AR124992A1 - Vectores retrovirales - Google Patents
Vectores retroviralesInfo
- Publication number
- AR124992A1 AR124992A1 ARP220100434A ARP220100434A AR124992A1 AR 124992 A1 AR124992 A1 AR 124992A1 AR P220100434 A ARP220100434 A AR P220100434A AR P220100434 A ARP220100434 A AR P220100434A AR 124992 A1 AR124992 A1 AR 124992A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- plasmid
- seq
- haemagglutinin
- neuraminidase
- Prior art date
Links
- 230000001177 retroviral effect Effects 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 6
- 108050002093 Haemagglutinin-neuraminidases Proteins 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 239000013612 plasmid Substances 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 230000000241 respiratory effect Effects 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 108700004026 gag Genes Proteins 0.000 abstract 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0687—Renal stem cells; Renal progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un método para producir un vector retroviral pseudotipado con hemaglutinina-neuraminidasa (HN) y proteínas de fusión (F) de un paramixovirus respiratorio, y que comprende un promotor y un transgén, en donde dicho método comprende el uso de genes gag-pol optimizados con codones. Reivindicación 27: Un ácido nucleico que comprende genes gag-pol optimizados con codones, donde dicho ácido nucleico tiene al menos 80% de identidad de secuencia con SEQ ID Nº 1. Reivindicación 29: Un plásmido que comprende un ácido nucleico como se define en la reivindicación 27 ó 28, en donde opcionalmente: a. el plásmido comprende o consiste en una secuencia de ácido nucleico que tiene al menos 80% de identidad de secuencia con SEQ ID Nº 5; o b. el plásmido comprende o consiste en la secuencia de ácido nucleico de SEQ ID Nº 5. Reivindicación 30: Una célula huésped que comprende un ácido nucleico tal como se define en la reivindicación 27 ó 28, y/o un plásmido tal como se define en la reivindicación 29. Reivindicación 31: Un vector retroviral pseudotipado con hemaglutinina-neuraminidasa (HN) y proteínas de fusión (F) de un paramixovirus respiratorio que se puede obtener mediante un método como se define en cualquiera de las reivindicaciones 1 a 26.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2102832.9A GB202102832D0 (en) | 2021-02-26 | 2021-02-26 | Retroviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124992A1 true AR124992A1 (es) | 2023-05-24 |
Family
ID=75339978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100434A AR124992A1 (es) | 2021-02-26 | 2022-02-25 | Vectores retrovirales |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220273821A1 (es) |
| EP (1) | EP4298226A1 (es) |
| JP (1) | JP2024509789A (es) |
| KR (1) | KR20230154015A (es) |
| CN (1) | CN116940686A (es) |
| AR (1) | AR124992A1 (es) |
| AU (1) | AU2022225723A1 (es) |
| CA (1) | CA3208936A1 (es) |
| CL (1) | CL2023002470A1 (es) |
| CO (1) | CO2023012522A2 (es) |
| CR (1) | CR20230453A (es) |
| DO (1) | DOP2023000167A (es) |
| GB (1) | GB202102832D0 (es) |
| IL (1) | IL304808A (es) |
| MX (1) | MX2023009990A (es) |
| TW (1) | TW202246508A (es) |
| WO (1) | WO2022180411A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| GB0009760D0 (en) * | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| IL157335A0 (en) * | 2001-03-13 | 2004-02-19 | Novartis Ag | Lentiviral packaging constructs |
| SG10201810150UA (en) * | 2014-03-17 | 2018-12-28 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression in cone cells |
| GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
-
2021
- 2021-02-26 GB GBGB2102832.9A patent/GB202102832D0/en not_active Ceased
-
2022
- 2022-02-25 AR ARP220100434A patent/AR124992A1/es unknown
- 2022-02-25 US US17/681,647 patent/US20220273821A1/en active Pending
- 2022-02-25 CA CA3208936A patent/CA3208936A1/en active Pending
- 2022-02-25 MX MX2023009990A patent/MX2023009990A/es unknown
- 2022-02-25 TW TW111106985A patent/TW202246508A/zh unknown
- 2022-02-25 AU AU2022225723A patent/AU2022225723A1/en active Pending
- 2022-02-25 JP JP2023552051A patent/JP2024509789A/ja active Pending
- 2022-02-25 CN CN202280014096.XA patent/CN116940686A/zh active Pending
- 2022-02-25 WO PCT/GB2022/050524 patent/WO2022180411A1/en active Application Filing
- 2022-02-25 EP EP22708589.1A patent/EP4298226A1/en active Pending
- 2022-02-25 KR KR1020237029670A patent/KR20230154015A/ko unknown
- 2022-02-25 CR CR20230453A patent/CR20230453A/es unknown
-
2023
- 2023-07-27 IL IL304808A patent/IL304808A/en unknown
- 2023-08-21 CL CL2023002470A patent/CL2023002470A1/es unknown
- 2023-08-25 DO DO2023000167A patent/DOP2023000167A/es unknown
- 2023-09-22 CO CONC2023/0012522A patent/CO2023012522A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024509789A (ja) | 2024-03-05 |
| CL2023002470A1 (es) | 2024-01-26 |
| AU2022225723A1 (en) | 2023-08-10 |
| US20220273821A1 (en) | 2022-09-01 |
| CA3208936A1 (en) | 2022-09-01 |
| IL304808A (en) | 2023-09-01 |
| CN116940686A (zh) | 2023-10-24 |
| MX2023009990A (es) | 2023-10-16 |
| CR20230453A (es) | 2023-11-15 |
| KR20230154015A (ko) | 2023-11-07 |
| EP4298226A1 (en) | 2024-01-03 |
| CO2023012522A2 (es) | 2023-10-09 |
| DOP2023000167A (es) | 2023-11-30 |
| WO2022180411A1 (en) | 2022-09-01 |
| GB202102832D0 (en) | 2021-04-14 |
| TW202246508A (zh) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019014704A2 (es) | Agentes potenciadores para la transfección celular mejorada y/o la producción del vector raav | |
| BR112018011193A2 (pt) | métodos escalonáveis para produzir vetor viral adeno-associado (aav) recombinante em sistema de cultura celular em suspensão isento de soro adequado para uso clínico | |
| CA2553976A1 (en) | Method for producing minus-strand rna viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken .beta.-actin promoter | |
| AR097493A1 (es) | Constructos para expresar transgenes con el uso de elementos reguladores provenientes de genes ubiquitina de brachypodium | |
| AR123196A2 (es) | Polipéptido aislado que posee actividad pesticida, composición, molécula de adn, célula huésped, construcción, vector, métodos para producirlos y métodos para proteger plantas contra plagas | |
| JP2018534937A5 (es) | ||
| BRPI0719469C1 (pt) | vetores de expressão derivados de retrovírus e métodos para produzir um vírus infeccioso de sarampo | |
| Ohtani et al. | Identification of two distinct elements in the long terminal repeat of HTLV‐I responsible for maximum gene expression. | |
| CA2456169A1 (en) | Methods and compositions relating to improved lentiviral vector production systems | |
| ES2710708T3 (es) | Recombinasa a medida bien tolerada y muy específica para recombinar los sitios diana asimétricos en una pluralidad de cepas de retrovirus | |
| PE20240647A1 (es) | Estrategias de tratamiento del cancer mediante el uso de vectores de arenavirus | |
| WO2020257590A8 (en) | Production of vectors using phage origin of replication | |
| EA202190454A1 (ru) | Новый crispr-ассоциированный белок и его применение | |
| AR124992A1 (es) | Vectores retrovirales | |
| CO2023003453A2 (es) | Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados | |
| AR125191A1 (es) | Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso | |
| ES2099063T3 (es) | Transformacion del bacillus thuringiensis. | |
| CN103981202B (zh) | 一种构建犬瘟热病毒反向遗传系统的方法 | |
| AR102762A1 (es) | Secuencia de oligonucleótidos para uso en ingeniería de rutas metabólicas | |
| CO2021015432A2 (es) | Secuencia promotora y productos y usos relacionados de la misma | |
| NO905393D0 (no) | Nytt ekspresjonssystem fra sopp. | |
| CN111088256A (zh) | 食蟹猴u6启动子高效表达小rna及多个小rna表达的载体构建方法 | |
| MX2021009161A (es) | Acidos nucleicos recombinantes que contienen secuencias promotoras de alfaherpesvirus. | |
| WO2023062359A3 (en) | Novel viral regulatory elements | |
| AR119634A1 (es) | Nucleasas guiadas por arn y sus fragmentos activos y variantes y métodos de uso |